Gender differences in antipsychotic prescribing

International Review of Psychiatry

Volumn 22, Issue 5, 2010, Pages 472-484

  Smith, Shubulade ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIBIOTIC AGENT; ARIPIPRAZOLE; CARBAMAZEPINE; CHLORPROMAZINE; CITALOPRAM; CLOZAPINE; DULOXETINE; ERYTHROMYCIN; FLUOXETINE; FLUPHENAZINE; FLUVOXAMINE; GRAPEFRUIT EXTRACT; HALOPERIDOL; HYPERICUM PERFORATUM EXTRACT; KETOCONAZOLE; MOCLOBEMIDE; NEFAZODONE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PERPHENAZINE; PROPRANOLOL; QUETIAPINE; RISPERIDONE; SERTINDOLE; THIORIDAZINE; UNINDEXED DRUG; ZIPRASIDONE; ZUCLOPENTHIXOL;

ADVERSE OUTCOME; AKATHISIA; ARTICLE; BREAST CANCER; BREAST FEEDING; CANCER RISK; CHILD CARE; COLORECTAL CANCER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG METABOLISM; DYSLIPIDEMIA; EXTRAPYRAMIDAL SYMPTOM; GERIATRIC CARE; GLUCOSE INTOLERANCE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERPROLACTINEMIA; HYPERTENSION; LIFESPAN; METABOLIC SYNDROME X; OBESITY; OSTEOPOROSIS; PARKINSONISM; PREGNANCY; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; SEX DIFFERENCE; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL CLASS; SUDDEN DEATH; TARDIVE DYSKINESIA; TORSADE DES POINTES; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGING; ANTIPSYCHOTIC AGENTS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; PSYCHOTIC DISORDERS; REPRODUCTION; RISK FACTORS; SEX FACTORS; TREATMENT OUTCOME; WOMEN;

EID: 78149274905     PISSN: 09540261     EISSN: 13691627     Source Type: Journal    
DOI: 10.3109/09540261.2010.515965     Document Type: Article

References (109)

1. Alvares, A.P., Anderson, K.E., Conney, A.H., & Kappas, A. (1976). Interactions between nutritional factors and drug biotransformations in man. Proceedings of the National Academy Science of the United States of America, 73, 2501-2504.
2. Alvarez, P.A., & Pahissa, J. (2010). QT alterations in psychopharmacology: Proven candidates and suspects. Current Drug Safety, 5, 97-104.
3. Allison, D.B., Mentore, J.L., Heo, M., Chandler, L.P., Cappelleri, J.C., Infante, M.C., & Weiden, P.J. (1999). Antipsychotic-induced weight gain: A comprehensive research synthesis. American Journal of Psychiatry, 156, 1686-1696.
4. Altshuler, L.L., Cohen, L., Szuba, M.P., Burt, V.K., Gitlin, M., & Mintz, J. (1996). Pharmacologic management of psychiatric illness during pregnancy: Dilemmas and guidelines. American Journal of Psychiatry, 153, 592-606.
5. Anderson, G.D. (2008). Gender differences in pharmacological response. International Review of Neurobiology, 83, 1-10.
6. Anthony, M., & Berg, M.J. (2002). Biologic and molecular mechanisms for sex differences in pharmacokinetics, harmacodynamics, and pharmacogenetics: Part I. Journal of Women's Health and Gender Based Medicine, 11, 601-615.
7. Bell, R.C., Farmer, S., Ries, R., & Srebnik, D. (2009). Metabolic risk factors among Medicaid outpatients with schizophrenia receiving second-generation antipsychotics. Psychiatric Services, 60, 1686-1689.
8. Bennink, R., Peeters, M., Van den Maegdenbergh, V., Geypens, B., Rutgeerts, P., De Roo, M., & Mortelmans, L. (1998). Comparison of total and compartmental gastric emptying and antral motility between healthy men and women. European Journal of Nuclear Medicine, 25, 1293-1299.
9. Bobes, J., Garcia-Portilla, M.P., Rejas, J., Hernandez, G., Garcia-Garcia, M., Rico-Villademoros, F., & Porras, A. (2003). Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: The results of the EIRE study. Journal of Sex and Marital Therapy, 29, 125-147.
10. Burt, V.K., Suri, R., Altshule, L., Stowe, Z., Hendrick, V.C., & Muntea, E. (2001). The use of psychotropic medications during breast-feeding. American Journal of Psychiatry, 158, 1001-1009.
11. Bushe, C., Yeomans, D., Floyd, T., & Smith, S.M. (2008). Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics. Journal of Psychopharmacology, 22, S56-62.
12. Christodoulou, C., & Kalaitzi, C. (2005). Antipsychotic druginduced acute laryngeal dystonia: Two case reports and a mini review. Journal of Psychopharmacology, 19, 307-311.
13. Cormac, I., Ferriter, M., Benning, R., & Saul, C. (2004). Physical health and health risk factors in a population of long-stay psychiatric patients. The Psychiatrist, 29, 18-20.
14. Correll., C.U., & Carlson, H.E. (2006). Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 771-791.
15. Correll, C.U., & Schenk, E.M. (2008). Tardive dyskinesia and new antipsychotics. Current Opinion in Psychiatry, 21, 151-156.
16. Czekalla, J., Kollack-Walker, S., & Beasley Jr, C.M. (2001). Cardiac safety parameters of olanzapine: Comparison with other atypical and typical antipsychotics. Journal of Clinical Psychiatry, 62, S35-40.
17. Dashe, J.S., Twickler, D.M., Santos-Ramos, R., McIntire, D.D., & Ramus, R.M. (2006). Alpha-fetoprotein detection of neural tube defects and the impact of standard ultrasound. Amercian Journal of Obstetrics & Gynecology, 195, 1623-1628.
18. Duncan, E.J., Woolson, S.L., Hamer, R.M., & Dunlop, B.W. (2009). Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs population. International Clinical Psychopharmacology, 24, 204-213.
19. Expert Group. (2004). Consensus summary, Schizophrenia and Diabetes 2003 Expert Consensus Meeting, Dublin, 3-4 October 2003. British Journal of Psychiatry Supplement, 47, S112-114.
20. Fleeman, N., McLeod, C., Bagust, A., Beale, S., Boland, A., Dundar, Y., et al. (2010). The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: A systematic review and economic evaluation. Health Technology Assessment, 14, 1-157.
21. Galbally, M., Snellen, M., Walker, S., & Permezel, M. (2010). Management of antipsychotic and mood stabilizer medication in pregnancy: Recommendations for antenatal care. Australian & New Zealand Journal of Psychiatry, 44, 99-108.
22. Galdas, P.M., Cheater, F., & Marshall, P. (2005). Men and health help-seeking behaviour: Literature a review. Journal of Advances in Nursing, 49, 616-623.
23. Gebhardt, S., Haberhausen, M., Heinzel-Gutenbrunner, M., Gebhardt, N., Remschmidt, H., Krieg, J.C., et al. (2009). Antipsychotic-induced body weight gain: Predictors and a systematic categorization of the long-term weight course. Journal of Psychiatric Research, 43, 620-626.
24. Gentile, S. (2004). Clinical utilization of atypical antipsychotics in pregnancy and lactation. Annals of Pharmacotherapy, 38, 265-271.
25. Goff, D.C., Sullivan, L.M., McEvoy, J.P., Meyer, J.M., Nasrallah, H.A., Daumit, G.L., et al. (2005). A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophrenia Research, 80, 45-53.
26. Haddad, P.M., & Wieck, A. (2004). Antipsychotic-induced hyperprolactinaemia: Mechanisms, clinical features and management. Drugs, 64, 2291-314.
27. Halliday, J., Farrington, S., Macdonald, S., MacEwan, T., Sharkey, V., & McCreadie, R. (2002). Nithsdale Schizophrenia Surveys 23: Movement disorders. 20-year review. British Journal of Psychiatry, 181, 422-427.
28. Harlow, B.L., Vitonis, A.F., Sparen, P., Cnattingius, S., Joffe, H., & Hultman, C.M. (2007). Incidence of hospitalization for postpartum psychotic and bipolar episodes in women with and without prior prepregnancy or prenatal psychiatric hospitalizations. Archives of General Psychiatry, 64, 42-48.
29. Haverkamp, W., Breithardt, G., Camm, A.J., Janse, M.J., Rosen, M.R., Antzelevitch, C., et al. (2000). The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: Clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. European Heart Journal, 21, 1216-1231.
30. Hiles, B.W. (1956). Hyperglycemia and glucosuria following chlorpromazine therapy (letter). Journal of the American Medical Association, 162, 1651.
31. Hippisley-Cox, J., Vinogradova, Y., Coupland, C., & Parker, C. (2007). Risk of malignancy in patients with schizophrenia or bipolar disorder: Nested case-control study. Archives of General Psychiatry, 64, 1368-1376.
32. Howard, L., Webb, R., & Abel, K. (2004). Safety of antipsychotic drugs for pregnant and breastfeeding women with non-affective psychosis. British Medical Journal, 329, 933-934.
33. Howard, L., Kirkwood, G., & Leese, M. (2007). Risk of hip fracture in patients with a history of schizophrenia. British Journal of Psychiatry, 190, 129-134.
34. Howes, O.D., Bhatnagar, A., Gaughran, F.P., Amiel, S.A., Murray, R.M., & Pilowsky, L.S. (2004). A prospective study of impairment in glucose control caused by clozapine without changes in insulin resistance. American Journal of Psychiatry, 161, 361-363.
35. Howes, O.D., Wheeler, M.J., Meaney, A.M., O'Keane, V., Fogelman, I., Blake, G., et al. (2005). Bone mineral density and its relationship to prolactin levels in patients taking antipsychotic treatment. Journal of Clinical Psychopharmacology, 25, 259-261.
36. Howes, O.D., Wheeler, M.J., Pilowsky, L.S., Landau, S., Murray, R.M., & Smith, S. (2007). Sexual function and gonadal hormones in patients taking antipsychotic treatment for schizophrenia or schizoaffective disorder. Journal of Clinical Psychiatry, 68, 361-367.
37. Jerrell, J.M., Bacon, J., Burgis, J.T., & Menon, S. (2009). Hyperprolactinemia-related adverse events associated with antipsychotic treatment in children and adolescents. Journal of Adolescent Health, 45, 70-76.
38. Juutilainen, A., Kortelainen, S., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (2004). Gender difference in the impact of type 2 diabetes on coronary heart disease risk. Diabetes Care, 27, 2898-2904.
39. Kamble, P., Chen, H., Sherer, J.T., & Aparasu, R.R. (2009). Use of antipsychotics among elderly nursing home residents with dementia in the US: An analysis of National Survey Data. Drugs Aging, 26, 483-492.
40. Keepers, G.A., Clappison, V.J., & Casey, D.E. (1983). Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Archives of General Psychiatry, 40, 1113-1117.
41. Koga, M. (2003). Clinical factors related to gains in body mass index (BMI) among patients under long-term antipsychotic treatment. Seishin Shinkeigaku Zasshi, 105, 473-488.
42. Kim, S.H., Nikolics, L., Abbasi, F., Lamendola, C., Link, J., Reaven, GM., & Lindley, S. (2010). Relationship between body mass index and insulin resistance in patients treated with second generation antipsychotic agents. Journal of Psychiatric Research, 44, 493-498.
43. Kinon, B.J., Gilmore, J.A., Liu, H., & Halbreich, U.M. (2003). Hyperprolactinemia in response to antipsychotic drugs: Characterization across comparative clinical trials. Psychoneuroendocrinology, 28, S69-82.
44. Knegtering, R., Castelein, S., Bous, H., Van Der Linde, J., Bruggeman, R., Kluiter, H., & van den Bosch, R.J. (2004). A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning. Journal of Clinical Psychopharmacology, 24, 56-61.
45. Lampe, J.W., King, I.B., Li, S., Grate, M.T., Barale, K.V., Chen, C., et al. (2000). Brassica vegetables increase and apiaceous vegetables decrease cytochrome P450 1A2 activity in humans: Changes in caffeine metabolite ratios in response to controlled vegetable diets. Carcinogenesis, 21, 1157-1162.
46. Lane H.Y., Chang Y.C., Chang W.H., Lin S.K., Tseng Y.T., Jann M.W. Effects of gender and age on plasma levels of clozapine and its metabolites: Analyzed by critical statistics Journal of Clinical Psychiatry 1999 60 36-40
47. Lear, S.A., Humphries, K.H., Kohli, S., Chockalingam, A., Frohlich, J.J., & Birmingham, C.L. (2007). Visceral adipose tissue accumulation differs according to ethnic background: Results of the Multicultural Community Health Assessment Trial (M-CHAT). American Journal of Clinical Nutrition, 86, 353-359.
48. Lear, S.A., Kohli, S., Bondy, G.P., Tchernof, A., & Sniderman, A.D. (2009). Ethnic variation in fat and lean body mass and the association with insulin resistance. Journal of Clinical Endocrinology & Metabolism, 94, 4696-4702.
49. Lin, C.H., Chen, M.C., Wang, S.Y., & Lin, C.Y. (2004). Predictive factors for QTc prolongation in schizophrenic patients taking antipsychotics. Journal of the Formosan Medical Association, 103, 437-441.
50. Liperoti, R., Onder, G., Landi, F., Lapane, K.L., Mor, V., Bernabei, R., & Gambassi, G. (2009). All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: A retrospective cohort study. Journal of Clinical Psychiatry, 70, 1340-1347.
51. Lipkovich, I., Deberdt, W., Csernansky, J.G., Buckley, P., Peuskens, J., Kollack-Walker, S., et al. (2007). Predictors of risk for relapse in patients with schizophrenia or schizoaffective disorder during olanzapine drug therapy. Journal of Psychiatric Research, 41, 305-310.
52. Lorena, S.L., Tinois, E., Brunetto, S.Q., Camargo, E.E., & Mesquita, M.A. (2004). Gastric emptying and intragastric distribution of a solid meal in functional dyspepsia: Influence of gender and anxiety. Journal of Clinical Gastroenterology, 38, 230-236.
53. McEvoy, J.P., Meyer, J.M., Goff, D.C., Nasrallah, H.A., Davis, S.M., Sullivan, L., et al. (2005). Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research, 80, 19-32.
54. McGrath, J., Saha, S., Welham, J., El Saadi, O., MacCauley, C., & Chant, D. (2004). A systematic review of the incidence of schizophrenia: The distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Medicine, 2, 113.
55. Meaney, A.M., Smith, S., Howes, O.D., O'Brien, M., Murray, R.M., & O'Keane, V. (2004). Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. British Journal of Psychiatry, 184, 503-508.
56. Meibohm, B., Beierle, I., & Derendorf, H. (2002). How important are gender differences in pharmacokinetics? Clinical Pharmacokinetics, 41, 329-342.
57. Meltzer, H.Y., Rabinowitz, J., Lee, M.A., Cola, P.A., Ranjan, R., Findling, R.L., & Thompson, P.A. (1997). Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance. American Journal of Psychiatry, 154, 475-482.
58. Mendhekar, D.N., War, L., Sharma, J.B., & Jiloha, R.C. (2002). Olanzapine and pregnancy. Pharmacopsychiatry, 35, 122-123.
59. Miller, L.J., & Finnerty, M. (1998). Family planning knowledge, attitudes and practices in women with schizophrenic spectrum disorders. Journal of Psychosomatics Obstetrics and Gynaecology, 19, 210-217.
60. Miller, R., Ream, G., McCormack, J., Gunduz-Bruce, H., Sevy, S., & Robinson, D.A. (2009). prospective study of cannabis use as a risk factor for non-adherence and treatment dropout in first-episode schizophrenia. Schizophrenia Research, 113, 138-144.
61. Mittendorfer, B. (2005). Insulin resistance: Sex matters. Current Opinion in Clinical Nutrition and Metabolic Care, 8, 367-372.
62. Müller, M.J., Regenbogen, B., Sachse, J., Eich, F.X., Härtter, S., & Hiemke, C. (2006). Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: A therapeutic drug monitoring study. Pharmacopsychiatry, 39, 41-46.
63. Munk-Olsen, T., Munk Laursen, T., Mendelson, T., Pedersen, C., Mors, O., & Mortensen, P.O. (2009). Risks and predictors of readmission for a mental disorder during the postpartum period. Archives of General Psychiatry, 66, 189-195.
64. Neighbors H.W., Caldwell C., Williams D.R., Nesse R., Taylor R.J., Bullard K.M., et al. Race ethnicity and the use of services for mental disorders: Results from the national survey of American Life Archives of General Psychiatry 2007 64 485-494
65. Newcomer, J.W. (2007). Antipsychotic medications: Metabolic and cardiovascular risk. Journal of Clinical Psychiatry, 68, S8-13.
66. Newcomer, J.W., Haupt, D.W., Fucetola, R., Melson, A.K., Schweiger, J.A., Cooper, B.P., & Selke, G. (2002). Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Archives of General Psychiatry, 59, 337-345.
67. Obias-Manno, D., Scott, P.E., Kaczmarczyk, J., Miller, M., Pinnow, E., Lee-Bishop, L., et al. (2007). The Food and Drug Administration Office of Women's Health: Impact of science on regulatory policy. Journal of Women's Health (Larchmt), 6, 807-817.
68. Olfson, M., Marcus, S.C., Corey-Lisle, P., Tuomari, A.V., Hines, P., & L'Italien, G.J. (2006). Hyperlipidemia following treatment with antipsychotic medications. American Journal of Psychiatry, 163, 1821-1825.
69. Osborn, D.P., Levy, G., Nazareth, I., Petersen, I., Islam, A., & King, M.B. (2007). Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database. Archives of General Psychiatry, 64, 242-249.
70. Paton, C., Esop, R., Young, C., & Taylor, D. (2004). Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs. Acta Psychiatrica Scandinavica, 110, 299-305.
71. Patton, S.W., Misri, S., Corral, M.R., Perry, K.F., & Kuan, A.J. (2002). Antipsychotic medication during pregnancy and lactation in women with schizophrenia: Evaluating the risk. Canadian Journal of Psychiatry, 47, 959-965.
72. Pinals, D.A., Malhotra, A.K, Missar, C.D., Pickar, D., & Breier, A. (1996). Lack of gender differences in neuroleptic response in patients with schizophrenia. Schizophrenia Research, 22, 215-222.
73. Pregelj, P. (2009). Neurobiological aspects of psychosis and gender. Psychiatria Danubina, 21, S128-131.
74. Raja, M., & Azzoni, A. (2001). Novel antipsychotics and acute dystonic reactions. International Journal of Neuropsychopharmacology, 4, 393-397.
75. Raja, M., & Azzoni, A. (2003). Sexual behaviour and sexual problems among patients with severe chronic psychoses. European Psychiatry, 18, 70-76.
76. Ramos-Ríos, R., Arrojo-Romero, M., Paz-Silva, E., Carballal- Calvo, F., Bouzón-Barreiro, J.L., Seoane-Prado, J., et al. (2010). QTc interval in a sample of long-term schizophrenia inpatients. Schizophrenia Research, 116, 35-43.
77. Ratnayake, T., & Libretto, S.E. (2002). No complications with risperidone treatment before and throughout pregnancy and during the nursing period. Journal of Clinical Psychiatry, 63, 76-77.
78. Robinson, D.G., Woerner, M.G., Alvir, J.M., Geisler, S., Koreen, A., Sheitman, B., et al. (1999a). Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. American Journal of Psychiatry, 156, 544-549.
79. Robinson, D., Woerner, M.G., Alvir, J.M., Bilder, R., Goldman, R., Geisler, S., et al. (1999b). Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Archives of General Psychiatry, 56, 241-247.
80. Rutten, B.P., & Mill, J. (2009). Epigenetic mediation of nvironmental influences in major psychotic disorders. Schizophrenia Bulletin, 35, 1045-1056.
81. Ryan, M.C., Collins, P., & Thakore, J.H. (2003). Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. American Journal of Psychiatry, 160, 284-289.
82. Salokangas, R.K. (2004). Gender and the use of neuroleptics in schizophrenia. Schizophrenia Research, 66, 41-49.
83. Scandlyn, M.J., Stuart, E.C., & Rosengren, R.J. (2008). Sex-specific differences in CYP450 isoforms in humans. Expert Opinion in Drug Metabolism and Toxicology, 4, 413-424.
84. Schneeweiss, S., Setoguchi, S., Brookhart, A., Dormuth, C., & Wang, P.S. (2007). Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. Canadian Medical Association Journal, 176, 627-632.
85. Seeman, M.V. (1982). Gender differences in schizophrenia. Canadian Journal of Psychiatry, 27, 107-112.
86. Smith, S., Wheeler, M.J., Murray, R., & O'Keane, V. (2002). The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic- pituitary-gonadal axis. Journal of Clinical Psychopharmacology, 22, 109-114.
87. Smith, S.M., O'Keane, V., & Murray, R. (2002). Sexual dysfunction in patients taking conventional antipsychotic medication. British Journal of Psychiatry, 181, 49-55.
88. Smith, S., Yeomans, D., Bushe, C.J., Eriksson, C., Harrison, T., Holmes, R., et al. (2007). A well-being programme in severe mental illness. Baseline findings in a UK cohort. International Journal of Clinical Practice, 61, 1971-1978.
89. Szymanski, S., Lieberman, J.A., Alvir, J.M., Mayerhoff, D., Loebel, A., Geisler, S., et al. (1995). Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. American Journal of Psychiatry, 152, 698-703.
90. Tang, Y.L., Mao, P., Li, F.M., Li, W., Chen, Q., Jiang, F., et al. (2007). Gender, age, smoking behaviour and plasma clozapine concentrations in 193 Chinese inpatients with schizophrenia. British Journal of Clinical Pharmacology, 64, 49-56.
91. Tang, Y.L., Gillespie, C.F., Epstein, M.P., Mao, P.X., Jiang, F., Chen, Q., et al. (2007). Gender differences in 542 Chinese inpatients with schizophrenia. Schizophrenia Research, 97, 88-96.
92. Taylor, D., Young, C., Mohamed, R., Paton, C., & Walwyn, R. (2005). Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receiving antipsychotic drugs. Journal of Psychopharmacology, 19, 182-186.
93. Taylor, T.M., O'Toole, M.S., Ohlsen, R.I., Walters, J., & Pilowsky, L.S. (2003). Safety of quetiapine during pregnancy. American Journal of Psychiatry, 160, 588-589.
94. Thanvi, B., & Treadwell, S. (2009). Drug induced Parkinsonism: A common cause of Parkinsonism in older people. Postgraduate Medical Journal, 85, 322-326.
95. Thonnard-Neumann, E. (1968). Phenothiazines and diabetes in hospitalized women. American Journal of Psychiatry, 124, 978-982.
96. Usall, J., Suarez, D., Haro, J.M., & SOHO Study Group (2007). Gender differences in response to antipsychotic treatment in outpatients with schizophrenia. Psychiatry Research, 153, 225-231.
97. Valdimarsdóttir, U., Hultman, C., Harlow, B., Cnattingius, S., & Sparén, P. (2009). Psychotic illness in first-time mothers with no previous psychiatric hospitalizations: A population-based study. Public Library of Science: Medicine, 6, e13.
98. Van Harten, P.N., & Kahn, R.S. (1999). Tardive dystonia. Schizophrenia Bulletin, 25, 741-748.
99. Van Os, J., Walsh, E., van Horn, E., Tattan, T., Bale, R., & Thompson, S.G. (1999). Tardive dyskinesia in psychosis: Are women really more at risk? UK700 Group. Acta Psychiatrica Scandinavica, 99, 288-293.
100. Verma, S.K., Subramaniam, M., Liew, A., & Poon, L.Y. (2009). Metabolic risk factors in drug-naive patients with first-episode psychosis. Journal of Clinical Psychiatry, 70, 997-1000.
101. Viguera, A.C., Whitfield, T., Baldessarini, R.J., Newport, D.J., Stowe, Z., Reminick, A., et al. (2007). Risk of recurrence in women with bipolar disorder during pregnancy: Prospective study of mood stabilizer discontinuation. American Journal of Psychiatry, 164, 1817-1824.
102. Wang, P.S., Gilman, S.E., Guardino, M., Christiana, J.M., Morselli, P.L., Mickelson, K., & Kessler, R.C. (2000). Initiation of and adherence to treatment for mental disorders: Examination of patient advocate group members in 11 countries. Medical Care, 38, 926-936.
103. Wang, P.S., Walker, A.M., Tsuang, M.T., Orav, E.J., Glynn, R.J., Levin, R., & Avorn, J. (2002). Dopamine antagonists and the development of breast cancer. Archives of General Psychiatry, 59, 1147-1154.
104. Wang, P.S., Schneeweiss, S., Avorn, J., Fischer, M.A., Mogun, H., Solomon, D.H., & Brookhart, M.A. (2005). Risk of death in elderly users of conventional vs. atypical antipsychotic medications. New England Journal of Medicine, 353, 2335-2341.
105. Wisner, K.L., Perel, J.M., & Findling, R.L. (1996). Antidepressant treatment during breast-feeding. American Journal of Psychiatry, 153, 1132-1137.
106. Wolbold, R., Klein, K., Burk, O., Nüssler, A.K., Neuhaus, P., Eichelbaum, M., et al. (2003). Sex is a major determinant of CYP3A4 expression in human liver. Hepatology, 38, 978-988.
107. Yoshida, K., Smith, B., Craggs, M., & Kumar, R. (1998). Neuroleptic drugs in breast-milk: A study of pharmacokinetics and of possible adverse effects in breast-fed infants. Psychological Medicine, 28, 81-91.
108. Yoshida, K., & Yamashita, H. (2003). Treatment strategy for women with puerperal psychiatric disorders - Psychopharmacotherapy and its impact on fetus and breast-fed infants. Seishin Shinkeigaku Zasshi, 105, 1136-1144.
109. Zhang, X.Y., Chen da, C., Qi, L.Y., Wang, F., Xiu, M.H., Chen, S., et al. (2009). Gender differences in the prevalence, risk and clinical correlates of tardive dyskinesia in Chinese schizophrenia. Psychopharmacology (Berlin), 205 647-654.